The candidate vaccine’s next steps will be going through the FDA’s Biologics License Application process.
News|Slideshows|August 28, 2024
ICYMI: Drug Topics July/August 2024 Issue
Author(s)Lauren Massaro
Don’t miss out on the latest pharmacy insights in the Drug Topics July/August issue.
Advertisement
The July/August 2024 issue of Drug Topics includes important insights on the pivotal rejection of MDMA by an independent FDA Advisory Panel, the importance of patient advocacy in enacting pharmacy change—"Either get into politics or get out of pharmacy," our columnist writes—CDC-backed vaccine recommendations, and more.
To read these stories and more,
Don’t get left behind: Sign up today for our
Advertisement
Related to this article
The Milken Institute released survey results alongside new data regarding the need for pharmacists in extending effective GLP-1 care.
Through the ACCESS program, Mark Ey, RPh, notes that pharmacies can now start billing for a variety of services they’ve already been providing.
The medication significantly increased risk of pregnancy loss when compared with macrolide antibiotics, amoxicillin, and topical clindamycin for acne.
In part 3, Rebold explores improving the ART formulary protocol through introducing pharmacist-led transition-of-care services.
Our hosts explore why ketone monitoring matters, what pharmacists should know about Libre Duo, and how patient education can support proactive care management.
Mark Ey, RPh, details the patient-focused factors of the ACCESS to Pharmacy Care Program and the ways in which valued care translates to reimbursement.
A new option for adults who have experienced stroke will now be available to further reduce future risk.
Advertisement
Advertisement
Trending on Drug Topics
1
FDA Adds NAION Eye Risk Warning to All GLP-1 Labels
2
The Pharmacy Model Creating New Billing Pathways, Improved Recognition
3
New Report Finds Pharmacies Key in Long-Term GLP-1 Success
4
Vaxcyte’s VAX-31 Pneumococcal Vaccine Meets All Phase 3 Primary Goals
5